News and events
News
Our articles in News are shown below.
-
Under pressure
Technology developed at the University of Cambridge which facilitates electrical measurements under pressure is to be commercialised by easyLab, a Reading-based designer and manufacturer of equipment for high-pressure applications.
-
Lumora develops technique to improve speed and sensitivity of molecular diagnostics
A new technique for in vitro molecular diagnostics could provide increased speed, sensitivity and reproducibility over current methods, through the use of stem primers.
-
BlueGnome’s screening platform triples rate of embryo implantation in IVF
The screening platform developed by University of Cambridge spin-out BlueGnome triples rates of embryo implantation for women undergoing in vitro fertilisation (IVF) treatment, according to a recent study.
-
Eight19 launches new fund to bring affordable solar power to rural Africa
Cambridge spin-out company Eight19 has launched a new charitable fund which will help bring affordable solar lighting to rural off-grid communities in East Africa.
-
Enval secures funding for first commercial plant
University of Cambridge spin-out Enval has secured further funding for the commercialisation of its technology for the recycling of plastic-aluminium laminate packaging.
-
Cambridge partners with Lilly in Open Innovation Drug Discovery Platform
The University of Cambridge is partnering with global pharmaceutical company Eli Lilly and Company in an active collaboration programme helping to find and develop potential new medicines, particularly in the areas of greatest need.
-
Cambridge Enterprise announces 2011 results
Income generated from the University of Cambridge’s commercialisation activities continued to rise in 2011, as did the number of intellectual property, consultancy and equity agreements signed on behalf of the University and its researchers.
-
Research reveals shocking new way to create nanoporous materials
Research demonstrates simple, scaleable method with realistic capability of industrial cross-over.
-
Horizon Discovery announces collaboration with the National Cancer Institute and the National Human Genome Research Institute
Horizon’s rAAV gene targeting to be applied in cancer research programmes, enabling the NCI and NHGRI to engineer human isogenic disease models.
-
New treatment for multiple sclerosis: Cambridge University translates research at the bench into a drug at the bedside
Phase III clinical trials for new MS drug very positive.